233 related articles for article (PubMed ID: 25971363)
41. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
42. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
[TBL] [Abstract][Full Text] [Related]
43. Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System.
Omidvar N; Tekin N; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Auewarakul C; Sritana N; Cerci JJ; Dimamay MP; Gyorke T; Redondo F; Nair R; Gorospe C; Paez D; Fanti S; Ozdag H; Padua RA; Carr R
Acta Haematol; 2020; 143(6):600-602. PubMed ID: 32187599
[No Abstract] [Full Text] [Related]
44. Vanishing right ventricular outflow obstruction: an unusual presentation of mediastinal lymphoma.
Kolhari VB; Nagesh CM; Singh Y; Manjunath CN
Eur Heart J; 2013 Jul; 34(25):1784. PubMed ID: 23641012
[No Abstract] [Full Text] [Related]
45. Disseminated Lymphoma Evolving into Neurolymphomatosis during Mid-cycle of Chemotherapy Detected by (18)F-FDG PET/CT.
Tong AK; Neo SH; Kok TY
Ann Acad Med Singap; 2015 Nov; 44(11):545-7. PubMed ID: 27089963
[No Abstract] [Full Text] [Related]
46. Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials.
Bieri S; Roggero E; Zucca E; Bertoni F; Pianca S; Sanna P; Pedrinis E; Bernier J; Cavalli F
Leuk Lymphoma; 1999 Nov; 35(5-6):537-44. PubMed ID: 10609791
[TBL] [Abstract][Full Text] [Related]
47. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve.
Advani P; Paulus A; Murray P; Jiang L; Goff R; Pooley R; Jain M; Garner H; Foran J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e117-20. PubMed ID: 25617034
[No Abstract] [Full Text] [Related]
48. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
49. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
50. Diffuse involvement of the heart and great vessels in primary cardiac lymphoma.
Kaderli AA; Baran I; Aydin O; Bicer M; Akpinar T; Ozkalemkas F; Yesilbursa D; Gullulu S
Eur J Echocardiogr; 2010 Jan; 11(1):74-6. PubMed ID: 19759028
[TBL] [Abstract][Full Text] [Related]
51. A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass.
Yousif P; Kotecha A; Thakur A; Ismail HM
Am J Case Rep; 2019 Dec; 20():1821-1825. PubMed ID: 31809493
[TBL] [Abstract][Full Text] [Related]
52. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
53. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
55. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
[TBL] [Abstract][Full Text] [Related]
56. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
57. Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy.
Hashimoto Y; Omura H; Tokuyasu Y; Nakamoto S; Tanaka T
Intern Med; 2019 Dec; 58(23):3455-3459. PubMed ID: 31391392
[TBL] [Abstract][Full Text] [Related]
58. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
[TBL] [Abstract][Full Text] [Related]
59. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
60. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
